Research programme: GABA A receptor inverse agonists - Merck Sharp & Dohme

Drug Profile

Research programme: GABA A receptor inverse agonists - Merck Sharp & Dohme

Alternative Names: IAα5-2

Latest Information Update: 29 Jan 2008

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Thiophenes
  • Mechanism of Action GABA A alpha 5 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Jul 2004 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)
  • 29 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to the pharmacokinetics section
  • 01 Jul 2003 Removed Research programme from the title
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top